Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.

ABSTRACT:

Introduction

The outcomes of refractory or relapsed diffuse large B-cell lymphoma are generally poor, especially those relapsed or progressed within 12 months from diagnosis named as early chemoimmunotherapy failure (ECF), with a 2-year OS of 24.7%. Due to the dismal outcome, early recognition of ECF and developing targeted innovative treatments to improve patient prognosis are urgent.

Methods

This study recruited 2038 newly diagnosed DLBCL patients treated with R-CHOP/RminiCHOP or R-CHOP-based immunochemotherapy in Ruijin hospital and 411 hospital from December 1997 to December 2020.

Results

Compared to the control group, ECF patients were significantly associated with elderly age, advanced Ann Arbor stage, elevated serum LDH, poor performance status, multiple extran

SUBMITTER: Dong YY 

PROVIDER: S-EPMC12206878 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature